Aligos therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif., march 14, 2025 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”, “company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the compensation committee of the company's board of directors granted a non-qualified stock option to purchase an aggregate of 4,000 shares of the company's stock (the “inducement grant”) to a newly hired employee on march 11, 2025 (the “grant date”), in connection with the commencement of employment.
ALGS Ratings Summary
ALGS Quant Ranking